Our analysis revealed that patients with lower NNMT expression in COAD, GBM, and OV showed increased sensitivity to chemotherapies, while those with higher NNMT expression in BRCA benefited more from such treatments (Fig. 7A). This evidence concerns the gene NNMT and glioblastoma.